MedTrace Logo

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 257

Last updated 2026-03-24

No results posted yet for this study

Summary

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Conditions

  • Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
  • Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
  • Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
  • Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
  • Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)

Interventions

BIOLOGICAL

Volrustomig

IV Infusion

DRUG

Cisplatin

IV Infusion

DRUG

Carboplatin

IV Infusion

DRUG

Paclitaxel

IV Infusion

DRUG

5-FU

IV Infusion

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-22
Primary Completion
2028-11-30
Completion
2028-11-30
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • China
  • South Korea
  • Taiwan
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06535607 on ClinicalTrials.gov